Beating expectations for the second quarter, Bristol-Myers Squibb Co. touted the stability of its PD-1 inhibitor Opdivo in second-line metastatic non-small cell lung cancer (NSCLC), as well as the diversity of the immuno-oncology franchise overall, especially strong performance of the Opdivo/Yervoy combo in renal cancer.
Bristol reported second quarter sales of about $1.6bn for Opdivo (nivolumab) on July 26, up by 36% year-over-year, helping to...